WO2007046631A1 - Method for manufacturing high purified factor ix - Google Patents
Method for manufacturing high purified factor ix Download PDFInfo
- Publication number
- WO2007046631A1 WO2007046631A1 PCT/KR2006/004237 KR2006004237W WO2007046631A1 WO 2007046631 A1 WO2007046631 A1 WO 2007046631A1 KR 2006004237 W KR2006004237 W KR 2006004237W WO 2007046631 A1 WO2007046631 A1 WO 2007046631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- exchange chromatography
- solution
- highly purified
- cation exchange
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 229960004222 factor ix Drugs 0.000 title claims description 82
- 108010076282 Factor IX Proteins 0.000 claims abstract description 107
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 9
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 91
- 239000000243 solution Substances 0.000 claims description 28
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 238000005277 cation exchange chromatography Methods 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 10
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 239000006167 equilibration buffer Substances 0.000 claims description 8
- 238000005571 anion exchange chromatography Methods 0.000 claims description 7
- -1 Sephacel Polymers 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 238000001728 nano-filtration Methods 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012507 Sephadex™ Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000012149 elution buffer Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000011534 wash buffer Substances 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 230000002779 inactivation Effects 0.000 abstract description 8
- 229940105774 coagulation factor ix Drugs 0.000 abstract description 5
- 230000000415 inactivating effect Effects 0.000 abstract description 5
- 238000004255 ion exchange chromatography Methods 0.000 abstract description 4
- 102000013831 Coagulation factor IX Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 16
- 238000000746 purification Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 10
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 7
- 239000003114 blood coagulation factor Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000009429 hemophilia B Diseases 0.000 description 6
- 102100023804 Coagulation factor VII Human genes 0.000 description 5
- 108010023321 Factor VII Proteins 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- 229940012413 factor vii Drugs 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002885 thrombogenetic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 102400000069 Activation peptide Human genes 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108010056902 Mononine Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000003027 hypercoagulation Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940090053 mononine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Definitions
- the present invention relates to a method for manufacturing a highly purified human blood coagulation factor IX, and more preferably, to a method for manufacturing a highly purified human blood coagulation factor IX by subjecting a plasma- derived or recombinant material containing a human blood coagulation factor IX, and by using of ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and viruses.
- a human blood coagulation factor IX (abbreviated to Factor IX) is a glycoprotein that is indispensable for a coagulation cascade. Hemophilia B is caused by the absence or deficiency of Factor IX due to a hereditary cause or a pathological cause.
- the hemophilia B is a rare hereditary disease that primarily affects newborn male babies having prevalence of one of 30,000 ⁇ 50,000. Cure of the hemophilia B is performed by administering Factor IX concentrates.
- Factor IX is synthesized in the liver and has similar features like as other vitamin Independent glycoproteins.
- Vitamin K-dependent glycoproteins include Factor II, Factor VII, Factor X, and so on.
- the Factor IX a kind of serine protease, is a monomeric glycoprotein containing about 17.5% glucose comprising 4.7% hexose, 6.8% N- acetylhexsamine, and 6% sialic acid.
- Factor IX has a molecular weight of 55 ⁇ 75 kDa (Daltons) according to the amount of carbohydrate contents. The exact molecular weight of only proteins, which is calculated based on amino acid sequences, is 47,054 Da.
- Factor IX is activated by the release of activation peptide fragments consisting of 35 amino acids due to cleavage of an arginine(Arg)-alanine(Ala) bond by Factor XIa at sites between Arg and Ala and between Arg and VaI .
- Factor IX a phospholipid complex comprising Factor Vila, Factor III, and calcium ion (Ca + ) (Fig. 1).
- Factor IX is present in the human plasma in a very low concentration of about 0.1 ⁇ M (5 D/D).
- high doses of whole blood or plasma should be required. Such high dose blood administration may, however, involve severe side effects, which results from excessive administration of other proteins such as fibrinogen in the plasma.
- Factor IX concentrates were developed for the first time in the late 1950s. To isolate Factor IX concentrates, Factor IX is first collected from the plasma and then adsorbed into barium sulfate, followed by precipitation and washing to remove other protein components from Factor IX adsorbed into barium sulfate. Later, barium sulfates were replaced with tricalcium phosphates which are nontoxic salts. The process of isolating Factor IX concentrates by adsorption and precipitation may also cause concentration of other vitamin K-dependent glycoproteins such as Factor II, Factor VII, Factor X, and so on. These concentrates are termed a prothrombin complex concentrates (PCC). Factor IX complex obtained above has been widely used as the therapeutic agent of the hemophilia B since the 1960s.
- PCC prothrombin complex concentrates
- Factor II, Factor VII, Factor X, and other proteins from the Factor IX complex was attempted, and a highly purified Factor IX had become commercially available from the 1990s.
- the highly purified Factor IX was obtained by subjecting concentrated Factor IX complex to anion exchange chromatography followed by heparin gel or monoclonal antibody chromatography, thereby removing Factor II, Factor VII, Factor X, and other proteins from the Factor IX complex.
- Factor IX complex is currently being replaced by the highly purified Factor IX.
- a recombinant coagulation factor IX using the Chinese hamster ovary (CHO) cell line was developed and manufactured by Genetic Institute in the trade name of Benefix TM in 1997.
- Virus inactivation is generally performed by solvent/detergent (SfD) treatment.
- SfD solvent/detergent
- affinity chromatography can be added in the process of virus inactivation.
- the most effective method of virus removal is a nanofiltration technique using a 20 nm grade nanofilter. However, this technique requires a process of preliminarily purifying a coagulation factor to obtain a highly purified coagulation factor, otherwise aggregation or clogging of proteins make the nanofilter useless.
- Fig. 2 is a process flow diagram illustrating a method for manufacturing a highly purified Factor IX according to the present invention.
- a solution containing Factor IX used in the present invention is not particularly restricted in their forms.
- cryo- precipitate-free human plasma is preferably used as a starting material.
- the starting substance include plasma fractions, cell culture broth of recombinant Factor IX, and solution containing the Factor IX, and so on.
- a method for manufacturing a highly purified Factor IX from a material containing the Factor IX as a starting material provided aprimarily eluting a solution containing the Factor IX by anion exchange chromatography, followed inactivating viruses by Solvent/Detergent (SfD) treatment, secondarily eluting the resultant by anion exchange chromatography, concentrating and filtrating the secondarily eluted product, obtaining eluate by heparin affinity chromatography, collecting an unbound solution by cation exchange chromatography for further purification, and removing viruses by subjecting the collected unbound solution to nanofiltration.
- Solvent/Detergent SfD
- the eluate is purified by heparin affinity chromatography using heparin as a ligand for a blood coagulation factor. Then, the eluate is subjected to cation exchange chromatography to collect an unbound solution that is not adsorbed into a cation exchanger, thereby removing other impurities remaining in the eluate.
- heparin is used as a ligand in the heparin affinity chromatography
- resin materials including Sepharose and agarose and polyacrylamide can be used as a support, but not limited to herein.
- a heparin Sepharose 6FF column is currently preferred.
- an equilibration buffer used prior to application of the solution containing Factor IX and a solution containing Factor IX preferably have ion strengths of not greater than 20 mS/cm and pH range of between 5.0 and 9.0.
- a washing buffer used for washing other proteins adsorbed into a resin preferably has ion strengths of 10 ⁇ 20 mS/cm.
- an elution buffer used for eluting the solution containing Factor IX preferably has ion strengths of 20 ⁇ 50 mS/ cm.
- a particularly preferred embodiment relates to the isolation of Factor IX by cation exchange chromatography, for example by using the following materials: weak cations such as carboxymethyl- (CM-), or carboxy- (C-); and strong cations such as sulfo- (S-), sulfomethyl- (SM-), sulfoethyl- (SE-), sulfopropyl- (SP-), or phospho- (P-).
- weak cations such as carboxymethyl- (CM-), or carboxy- (C-)
- strong cations such as sulfo- (S-), sulfomethyl- (SM-), sulfoethyl- (SE-), sulfopropyl- (SP-), or phospho- (P-).
- a variety of column resins can be used, including Sepharose, Sephadex, agarose, Sephacel, Polystyrene, Polyacrylate, Cellulose, and Toyope
- the cation exchange chromatography is preferably performed at a pH level in a range of between 3.0 and 6.0 such that an unbound solution that is not adsorbed into a column is collected for purification.
- an equilibration buffer used in the cation exchange chromatography can be used in various manners, the solution containing the equilibration buffer used prior to application of the solution containing Factor IX and the solution containing Factor IX have ion strength in a range of between about 10 and about 50 mS/cm.
- the present invention provides a method for manufacturing a highly purified Factor
- the method for manufacturing a highly purified Factor IX comprise of subjecting a plasma-derived or recombinant material containing a human blood coagulation factor IX to ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and viruses.
- FIG. 1 shows intrinsic and extrinsic coagulation pathways
- FIG. 2 is a process flow diagram illustrating a method for manufacturing a highly purified Factor IX according to the present invention
- Fig. 3 shows results of SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis identifying purity of Factor IX manufactured by the present invention and other commercially available Factor IX products in non-reducing (A) and reducing (B) condition.
- SDS-PAGE SDS-polyacrylamide gel electrophoresis
- FIG. 4 is a graph showing the results of tests for evaluating stability of activity expressed as the t
- a cryoprecipitate-free plasma or cell culture medium of recombinant Factor IX as a starting material was mixed with DEAE-Sephadex A-50, prewashed with buffer, and stirred for 2 hours at 4 0 C. Subsequently, the gel to which Factor IX was now bound was separated by filtration or centrifugation. After washing, Factor IX was eluted by a buffer with high salt concentration. A pH of the eluate was appropriately adjusted to 7.5 and then the eluate was subjected to dialysis and concentration for storage at -7O 0 C. The concentrate was aliquoted and measured the activity under the standards and test methods of blood formulations and recombinant formulations as stipulated by the KFDA (Korea Food and Drug Administration).
- FIG. 3 shows results of SDS-PAGE analysis carried out to determine purity of Factor IX manufactured by the present invention and other commercially available Factor IX products. As shown in Fig. 3, Factor IX manufactured by the present invention had little impure proteins, suggesting that they had higher purity levels than other Factor IX products.
- EXAMPLE 7 Purification of Factor IX from cell culture medium
- CHO cells cloned with the Factor IX were cultured in serum free media, and a 5L culture media removed the CHO cells was treated as the same methods as mentioned in Examples 1 through 3, except of S/D treatment, and thereby Factor IX was purified.
- Table 7 shows various data items, including specific activity, purification fold, yield, and so on.
- EXAMPLE 8 Virus inactivation and removal process
- clearance tests were conducted on various viruses, including HIV (Human Immunodeficiency Virus), BHV (Bovine Herpes Virus), BVDV (Bovine Viral Diarrhea Virus), HAV (Hepatitis A Virus), EMCV (Encephalo Mycarditis Virus), PPV (Porcine Parvovirus), and so on.
- HIV Human Immunodeficiency Virus
- BHV Bovine Herpes Virus
- BVDV Bovine Viral Diarrhea Virus
- HAV Hepatitis A Virus
- EMCV Electrodencephalo Mycarditis Virus
- PPV Porcine Parvovirus
- Virus clearance values shown in Table 8 are log factors obtained by subtracting titers of processing from titers of stock viruses used, while virus reduction values shown in Table 9 are log factors of values obtained by subtracting titers of processing from spiked titers of stock viruses after spiking the stock viruses into target viruses.
- the present invention is industrially applicable by providing a method for manufacturing a highly purified Factor IX comprise of subjecting a plasma-derived or recombinant material containing a human blood coagulation factor IX to ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and viruses.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method for manufacturing a highly purified human blood coagulation factor IX, and more preferably, to a method for manufacturing a highly purified human blood coagulation factor IX by subjecting a plasma-derived or recombinant material containing a human blood coagulation factor IX, and by using of ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and viruses.
Description
Description
METHOD FOR MANUFACTURING HIGH PURIFIED FACTOR
IX
Technical Field
[1] The present invention relates to a method for manufacturing a highly purified human blood coagulation factor IX, and more preferably, to a method for manufacturing a highly purified human blood coagulation factor IX by subjecting a plasma- derived or recombinant material containing a human blood coagulation factor IX, and by using of ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and viruses.
[2]
Background Art
[3] A human blood coagulation factor IX (abbreviated to Factor IX) is a glycoprotein that is indispensable for a coagulation cascade. Hemophilia B is caused by the absence or deficiency of Factor IX due to a hereditary cause or a pathological cause.
[4] The hemophilia B is a rare hereditary disease that primarily affects newborn male babies having prevalence of one of 30,000 ~ 50,000. Cure of the hemophilia B is performed by administering Factor IX concentrates.
[5] Factor IX is synthesized in the liver and has similar features like as other vitamin Independent glycoproteins. Vitamin K-dependent glycoproteins include Factor II, Factor VII, Factor X, and so on. The Factor IX, a kind of serine protease, is a monomeric glycoprotein containing about 17.5% glucose comprising 4.7% hexose, 6.8% N- acetylhexsamine, and 6% sialic acid. Factor IX has a molecular weight of 55 ~ 75 kDa (Daltons) according to the amount of carbohydrate contents. The exact molecular weight of only proteins, which is calculated based on amino acid sequences, is 47,054 Da. 12 gamma(γ) - carboxy glutamic acid domains play important roles in the activation of Factor IX and thus Factor IX is activated in the presence of phospholipid and calcium ion (Ca +). The diversity of isoelectric point (pi) of Factor IX depends on the kind and amount of carbohydrates present therein (Journal of Chromatography (1999) 844, 119).
[6] Factor IX is activated by the release of activation peptide fragments consisting of 35 amino acids due to cleavage of an arginine(Arg)-alanine(Ala) bond by Factor XIa at sites between Arg and Ala and between Arg and VaI . Factor IX without the
145 146 180 181 activated peptides is referred to an active form of Factor IX to distinguish the natural
form of Factor IX. The activation of Factor IX is also stimulated by a phospholipid complex comprising Factor Vila, Factor III, and calcium ion (Ca +) (Fig. 1). Factor IX is present in the human plasma in a very low concentration of about 0.1 μM (5 D/D). To treat a patient of hemophilia B, high doses of whole blood or plasma should be required. Such high dose blood administration may, however, involve severe side effects, which results from excessive administration of other proteins such as fibrinogen in the plasma.
[7] To overcome the side effects, Factor IX concentrates were developed for the first time in the late 1950s. To isolate Factor IX concentrates, Factor IX is first collected from the plasma and then adsorbed into barium sulfate, followed by precipitation and washing to remove other protein components from Factor IX adsorbed into barium sulfate. Later, barium sulfates were replaced with tricalcium phosphates which are nontoxic salts. The process of isolating Factor IX concentrates by adsorption and precipitation may also cause concentration of other vitamin K-dependent glycoproteins such as Factor II, Factor VII, Factor X, and so on. These concentrates are termed a prothrombin complex concentrates (PCC). Factor IX complex obtained above has been widely used as the therapeutic agent of the hemophilia B since the 1960s.
[8] A cold ethanol fraction process, which has been used to obtain albumin or globulin from plasma, was not suited to the separation of Factor IX complex. Thus, such conventional methods cannot be advantageously employed to purification of Factor IX. To solve the disadvantage, a column process using anion exchange chromatography has been developed. In the developed process, Factor Vlll-rich fractions are removed by cryoprecipitation, and Factor IX present in the cryoprecipitate-free plasma is adsorbed into an anion exchange resin and then is purified. However, this process may lead to adsorption of other proteins such as Factor II, Factor VII, or Factor X. In spite of such low purified Factor IX, the Factor IX complex is currently in use for the treatment of patients with the hemophilia B.
[9] Unfortunately, there are several findings reporting that administration of Factor IX complex cause incidence of symptoms such as venous thrombosis or disseminated intravascular coagulation (Thrombosis and Haemostasis (1995) 73, 584. Thrombosis and Haemostasis (1998) 79, 778). Such side effects presumably result from hyperco- agulation states caused by excessive amounts of coagulant proteins or unnecessary thrombogenic components of the concentrates when administered along with Factor IX.
[10] In order to alleviate side effects of Factor IX complex, an approach for removing
Factor II, Factor VII, Factor X, and other proteins from the Factor IX complex was attempted, and a highly purified Factor IX had become commercially available from the 1990s. The highly purified Factor IX was obtained by subjecting concentrated
Factor IX complex to anion exchange chromatography followed by heparin gel or monoclonal antibody chromatography, thereby removing Factor II, Factor VII, Factor X, and other proteins from the Factor IX complex. Thus Factor IX complex is currently being replaced by the highly purified Factor IX. A recombinant coagulation factor IX using the Chinese hamster ovary (CHO) cell line was developed and manufactured by Genetic Institute in the trade name of Benefix™ in 1997.
[11] The most serious problem in the treatment of blood-derived coagulation factors is the risk of viral infection due to plasma-derived viruses such as HIV, HBV, HCV, and the like. To ensure virus safety of the blood-derived coagulation factors, a virus removal is an indispensable process for ensuring the safety of blood-derived coagulation factors. Virus inactivation is generally performed by solvent/detergent (SfD) treatment. To achieve a more effective method of virus removal, a process of affinity chromatography can be added in the process of virus inactivation. The most effective method of virus removal is a nanofiltration technique using a 20 nm grade nanofilter. However, this technique requires a process of preliminarily purifying a coagulation factor to obtain a highly purified coagulation factor, otherwise aggregation or clogging of proteins make the nanofilter useless.
[12] Use of monoclonal antibodies is effective in selectively separating Factor IX from other coagulation factors. However, since animal cells has been used for antibody production, it is impossible to avoid the risks of viral transmission due to viruses derived from the animal cells. Furthermore, side effects can be appeared according to eluting antibodies during chromatography. It is also impossible to overcome the problem associated with viral infection when Factor IX is isolated from a recombinant cell culture media. Accordingly, there is a need a method for manufacturing a highly purified Factor IX, which has a purity of greater than 99% and a safety inactivated and removed of viruses.
[13]
Disclosure of Invention Technical Problem
[14] To solve the above problems, it is an object of the present invention to provide a method for manufacturing a highly purified Factor IX for eliminating side effects such as venous thrombosis or disseminated intravascular coagulation (DIC), which resulting from hypercoagulable states caused by excessive amounts of coagulant proteins or unnecessary thrombogenic components of the concentrates when administered along with Factor IX.
[15]
Technical Solution
[16] Hereinafter, a method for manufacturing a highly purified Factor IX according to the present invention will be described in detail.
[17] Fig. 2 is a process flow diagram illustrating a method for manufacturing a highly purified Factor IX according to the present invention. A solution containing Factor IX used in the present invention is not particularly restricted in their forms. In the method for manufacturing a highly purified Factor IX according to the present invention, cryo- precipitate-free human plasma is preferably used as a starting material. In addition, examples of the starting substance include plasma fractions, cell culture broth of recombinant Factor IX, and solution containing the Factor IX, and so on.
[18] In an embodiment of the present invention, a method for manufacturing a highly purified Factor IX from a material containing the Factor IX as a starting material provided aprimarily eluting a solution containing the Factor IX by anion exchange chromatography, followed inactivating viruses by Solvent/Detergent (SfD) treatment, secondarily eluting the resultant by anion exchange chromatography, concentrating and filtrating the secondarily eluted product, obtaining eluate by heparin affinity chromatography, collecting an unbound solution by cation exchange chromatography for further purification, and removing viruses by subjecting the collected unbound solution to nanofiltration.
[19] In detail, in order to remove impure proteins remaining in the plasma protein solution eluted by the anion exchange chromatography, the eluate is purified by heparin affinity chromatography using heparin as a ligand for a blood coagulation factor. Then, the eluate is subjected to cation exchange chromatography to collect an unbound solution that is not adsorbed into a cation exchanger, thereby removing other impurities remaining in the eluate.
[20] Since heparin is used as a ligand in the heparin affinity chromatography, a variety of resin materials including Sepharose and agarose and polyacrylamide can be used as a support, but not limited to herein. Particularly, a heparin Sepharose 6FF column is currently preferred. According to the present invention, when eluate is purified by heparin affinity chromatography, an equilibration buffer used prior to application of the solution containing Factor IX and a solution containing Factor IX preferably have ion strengths of not greater than 20 mS/cm and pH range of between 5.0 and 9.0. In addition, a washing buffer used for washing other proteins adsorbed into a resin preferably has ion strengths of 10 ~ 20 mS/cm. Furthermore, an elution buffer used for eluting the solution containing Factor IX preferably has ion strengths of 20 ~ 50 mS/ cm.
[21] A particularly preferred embodiment relates to the isolation of Factor IX by cation exchange chromatography, for example by using the following materials: weak cations such as carboxymethyl- (CM-), or carboxy- (C-); and strong cations such as sulfo- (S-),
sulfomethyl- (SM-), sulfoethyl- (SE-), sulfopropyl- (SP-), or phospho- (P-). In addition, a variety of column resins can be used, including Sepharose, Sephadex, agarose, Sephacel, Polystyrene, Polyacrylate, Cellulose, and Toyopearl. In the present invention, the cation exchange chromatography is preferably performed at a pH level in a range of between 3.0 and 6.0 such that an unbound solution that is not adsorbed into a column is collected for purification. Although an equilibration buffer used in the cation exchange chromatography can be used in various manners, the solution containing the equilibration buffer used prior to application of the solution containing Factor IX and the solution containing Factor IX have ion strength in a range of between about 10 and about 50 mS/cm. [22]
Advantageous Effects
[23] The present invention provides a method for manufacturing a highly purified Factor
IX. More particularly, the method for manufacturing a highly purified Factor IX according to the present invention comprise of subjecting a plasma-derived or recombinant material containing a human blood coagulation factor IX to ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and viruses.
[24]
Brief Description of the Drawings
[25] Fig. 1 shows intrinsic and extrinsic coagulation pathways;
[26] Fig. 2 is a process flow diagram illustrating a method for manufacturing a highly purified Factor IX according to the present invention;
[27] Fig. 3 shows results of SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis identifying purity of Factor IX manufactured by the present invention and other commercially available Factor IX products in non-reducing (A) and reducing (B) condition.
[28] M: Standard marker (myosin; 198kDa, galactosidase; 115kDa, BSA; 93kDa, ovalbumin; 49.8kDa, carbonic anhydrase; 35.8kDa, soybean trypsin inhibitor; 29.2kDa, lysozyme; 21.3kDa, aprotinin; 6.4kDa); Lane 1: highly purified Factor IX according to method mentioned in table 2; Lane 2: highly purified Factor IX according to method mentioned in table 3; Lane 3: highly purified Factor IX according to method mentioned in table 4; Lane 4: Facnyne (Greencross); Lane 5: Mononine (ZLB Behring); Lane 6: Octanyne (Octapharma); Lane 7: Berinin HS (ZLB Behring); and Lane 8: Immunine (Baxter).
[29] FIG. 4 is a graph showing the results of tests for evaluating stability of activity expressed as the titer carried out under CM-Sepharose fast flow (FF) purification conditions.
[30]
Best Mode for Carrying Out the Invention
[31] EXAMPLE 1: Purification of Factor IX by anion exchange chromatography
(conventional Process)
[32] A cryoprecipitate-free plasma or cell culture medium of recombinant Factor IX as a starting material was mixed with DEAE-Sephadex A-50, prewashed with buffer, and stirred for 2 hours at 40C. Subsequently, the gel to which Factor IX was now bound was separated by filtration or centrifugation. After washing, Factor IX was eluted by a buffer with high salt concentration. A pH of the eluate was appropriately adjusted to 7.5 and then the eluate was subjected to dialysis and concentration for storage at -7O0C. The concentrate was aliquoted and measured the activity under the standards and test methods of blood formulations and recombinant formulations as stipulated by the KFDA (Korea Food and Drug Administration).
[33] The above fraction containing Factor IX was subjected to perform a virus in- activation process by S/D treatment. A post-inactivation solution was adsorbed into a DEAE-toyopearl 650M column for second purification, followed by collecting an eluate.
[34]
[35] EXAMPLE 2: Purification of Factor IX by Heparin affinity chromatography
[36] 10 ml of the Factor IX complex solution prepared by the purification in Example 1 was conditioned to have an ion strength of not greater than 20 mS/cm, and pH 7.0, and an equilibration buffer (20 mM sodium citrate, pH 7.0) was induced to a Heparin- Sepharose 6FF column (column conditions: 1 cm in diameter, 18 cm in height, 1.0 ml/ min in flow rate, and room temperature) for equilibration. Meanwhile, a sample was loaded for adsorption, washed with the equilibration buffer plus 0.1 M NaCl, and then eluted using 0.25 M NaCl. A protein concentration of the eluate was determined and SDS-PAGE was carried out. The activity was measured using a coagulation timer KClO manufactured by Amelung, Germany.
[37] A specific activity of the eluate preparation from Example 1 was compared with that of the eluate preparation from Example 2. As the result, the specific activity of the Heparin-Sepharose 6FF column eluate of Example 2 was about 60-90 IU/mg, which showed an increase of at least 10 times that of the anion exchange column eluate of Example 1.
[38]
[39] EXAMPLE 3: Purification of Factor IX by cation exchange chromatography
[40] 10 ml of the Factor IX complex solution prepared by the purification in Example 2 was conditioned to have an ion strength of not greater than 20 mS/cm, and pH 4.0, and an equilibration buffer (20 mM citrate in 0.30 ~ 0.4 M NaCl, pH 4.0) was induced to an equilibrated CM-Sepharose 6FF column (column conditions: 1 cm in diameter, 5 cm in height, and 1.0 ml/min in flow rate) for collecting an unbound solution. A protein concentration of the unbound solution was determined and SDS-PAGE analysis was carried out. A specific activity of the unbound solution was at least 150 IU/mg. Fig. 3 shows results of SDS-PAGE analysis carried out to determine purity of Factor IX manufactured by the present invention and other commercially available Factor IX products. As shown in Fig. 3, Factor IX manufactured by the present invention had little impure proteins, suggesting that they had higher purity levels than other Factor IX products.
[41] [42] EXAMPLES 4 - 6: Large-scale Purification of Factor IX [43] To confirm large-scale feasibility of the highly purified Factor IX according to the present invention, scale-up experiments were carried out several times. In each of the scale-up experiments, various data items, including specific activity, purification fold, yield, and so on, are shown in Tables 1 through 6 below. [44] Table 1
[45] [46] Table 2
[47] [48] Table 3
[49] [50] Table 4
[51] [52] Table 5
[55] As shown in Tables 1 through 6, repeated practices of the present invention confirmed that highly purified Factors IX have the specific activity of at least 150 IU/ mg in final concentrates. The final concentrates were placed into vials each by an appropriate amount and lyophilized to be used as test samples of prolonged stability and preclinical samples.
[56] [57] EXAMPLE 7: Purification of Factor IX from cell culture medium [58] CHO cells cloned with the Factor IX were cultured in serum free media, and a 5L culture media removed the CHO cells was treated as the same methods as mentioned in Examples 1 through 3, except of S/D treatment, and thereby Factor IX was purified. Table 7 shows various data items, including specific activity, purification fold, yield,
and so on.
[59] Table 7
[60] [61] EXAMPLE 8: Virus inactivation and removal process [62] In virus inactivation and nanofiltration steps, clearance tests were conducted on various viruses, including HIV (Human Immunodeficiency Virus), BHV (Bovine Herpes Virus), BVDV (Bovine Viral Diarrhea Virus), HAV (Hepatitis A Virus), EMCV (Encephalo Mycarditis Virus), PPV (Porcine Parvovirus), and so on. The results are shown in Tables 8 and 9 below. Virus clearance values shown in Table 8 are log factors obtained by subtracting titers of processing from titers of stock viruses used, while virus reduction values shown in Table 9 are log factors of values obtained by subtracting titers of processing from spiked titers of stock viruses after spiking the stock viruses into target viruses.
[63] Table 8 Virus clearance on the processing of plasma-derived Factor IX
[64] [65] Table 9 Virus reduction on the processing of plasma-derived Factor IX
[66]
Industrial Applicability [67] The present invention is industrially applicable by providing a method for manufacturing a highly purified Factor IX comprise of subjecting a plasma-derived or recombinant material containing a human blood coagulation factor IX to ion chromatography and affinity chromatography and inactivating or removing viruses, thereby obtaining a highly purified, safe coagulation factor IX having a specific activity of above 150 IU/mg, with substantially inactivation or removal of all impure proteins and
viruses.
Claims
[1] A method for manufacturing a highly purified human blood coagulation factor
IX (Factor IX) using a material containing Factor IX as a starting material, the method comprising: collecting a solution containing Factor IX by performing anion exchange chromatography one or more times; eluting the solution containing Factor IX by performing heparin affinity chromatography; collecting an unbound solution by performing cation exchange chromatography and removing viruses by subjecting the collected unbound solution to nanofiltration.
[2] The method of claim 1, in the step on heparin affinity chromatography, wherein equilibration buffer and the solution containing the Factor IX have ion strength of not greater than 20 mS/cm at a pH range of 5.0 ~ 9.0, a washing buffer has ion strength of 10 ~ 20 mS/cm, and an elution buffer has ion strength of 20 ~ 50 mS/ cm.
[3] The method of claim 1, wherein a column functional group for the cation exchange chromatography is selected from the group consisting of car- boxymethyl- (CM-), carboxy- (C-), sulfo- (S-), sulfomethyl- (SM-), sulfoethyl- (SE-), sulfopropyl- (SP-), and phospho- (P-), and a column resin is selected from the group consisting of Sepharose, Sephadex, agarose, Sephacel, Polystyrene, Polyacrylate, Cellulose, and Toyopearl.
[4] The method of claim 1, wherein the collecting of the unbound solution by the cation exchange chromatography is performed at a pH in a range of between 3.0 and 6.0.
[5] The method of claim 1, wherein the collecting of the unbound solution by the cation exchange chromatography is performed using a solution containing an equilibration buffer and Factor IX having ion strength in a range of 10 ~ 50 mS/ cm.
[6] The method of claim 1, wherein the material containing Factor IX is a human plasma-derived or cell culture medium of recombinant Factor IX.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006800390241A CN101291951B (en) | 2005-10-18 | 2006-10-18 | Method for manufacturing high purified factor IX |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2005-0098235 | 2005-10-18 | ||
| KR1020050098235A KR100667860B1 (en) | 2005-10-18 | 2005-10-18 | Method for manufacturing high purified factor ix product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007046631A1 true WO2007046631A1 (en) | 2007-04-26 |
Family
ID=37867823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2006/004237 WO2007046631A1 (en) | 2005-10-18 | 2006-10-18 | Method for manufacturing high purified factor ix |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100667860B1 (en) |
| CN (1) | CN101291951B (en) |
| WO (1) | WO2007046631A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012037530A1 (en) | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph |
| US20150210754A1 (en) * | 2011-05-16 | 2015-07-30 | Omrix Biopharmaceuticals Ltd. | Immunoglobulin reduced in thrombogenic agents and preparation thereof |
| JP2017505780A (en) * | 2014-02-04 | 2017-02-23 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Use of cation exchange chromatography in flow-through mode to enrich post-translational modifications |
| CN115975997A (en) * | 2022-12-19 | 2023-04-18 | 成都蓉生药业有限责任公司 | Secondary ultrafiltration dialysate for purifying human blood coagulation factor IX and purification method |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104560925B (en) * | 2014-12-30 | 2017-11-03 | 山东泰邦生物制品有限公司 | A kind of method that activation prepares human thrombin in chromatography waste liquid from humanclottingfactorⅨ |
| CN111378029B (en) * | 2018-12-29 | 2023-05-05 | 四川远大蜀阳药业有限责任公司 | Preparation method of human coagulation factor IX |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457181A (en) * | 1987-10-23 | 1995-10-10 | Centre Regional De Transfusion Sanguine De Lille | Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use |
| WO1996025490A1 (en) * | 1995-02-15 | 1996-08-22 | Octapharma Ag | A process for the purification of vitamin k dependent coagulation factors by chromatography |
| JPH09286797A (en) * | 1996-04-18 | 1997-11-04 | Green Cross Corp:The | Heparin cofactor ii and its purification |
| US6893856B2 (en) * | 1993-12-10 | 2005-05-17 | Octapharma Ag | Process for preparing virus-inactivated factors 1X and X by membrane chromatography |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US545718A (en) * | 1895-09-03 | Blast-furnace | ||
| CN1297896A (en) * | 1999-11-29 | 2001-06-06 | 中国科学技术大学 | Method of extracting activated prothrombin X(FXa) effectively |
-
2005
- 2005-10-18 KR KR1020050098235A patent/KR100667860B1/en active IP Right Grant
-
2006
- 2006-10-18 WO PCT/KR2006/004237 patent/WO2007046631A1/en active Application Filing
- 2006-10-18 CN CN2006800390241A patent/CN101291951B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457181A (en) * | 1987-10-23 | 1995-10-10 | Centre Regional De Transfusion Sanguine De Lille | Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use |
| US6893856B2 (en) * | 1993-12-10 | 2005-05-17 | Octapharma Ag | Process for preparing virus-inactivated factors 1X and X by membrane chromatography |
| WO1996025490A1 (en) * | 1995-02-15 | 1996-08-22 | Octapharma Ag | A process for the purification of vitamin k dependent coagulation factors by chromatography |
| JPH09286797A (en) * | 1996-04-18 | 1997-11-04 | Green Cross Corp:The | Heparin cofactor ii and its purification |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012037530A1 (en) | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph |
| US20150210754A1 (en) * | 2011-05-16 | 2015-07-30 | Omrix Biopharmaceuticals Ltd. | Immunoglobulin reduced in thrombogenic agents and preparation thereof |
| US9796770B2 (en) * | 2011-05-16 | 2017-10-24 | Omrix Biopharmaceuticals Ltd. | Immunoglobulin reduced in thrombogenic agents and preparation thereof |
| JP2017505780A (en) * | 2014-02-04 | 2017-02-23 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Use of cation exchange chromatography in flow-through mode to enrich post-translational modifications |
| US12018046B2 (en) | 2014-02-04 | 2024-06-25 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| CN115975997A (en) * | 2022-12-19 | 2023-04-18 | 成都蓉生药业有限责任公司 | Secondary ultrafiltration dialysate for purifying human blood coagulation factor IX and purification method |
| CN115975997B (en) * | 2022-12-19 | 2023-11-17 | 成都蓉生药业有限责任公司 | Secondary ultrafiltration dialysate for purifying human coagulation factor IX and purification method |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100667860B1 (en) | 2007-01-11 |
| CN101291951A (en) | 2008-10-22 |
| CN101291951B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5457181A (en) | Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use | |
| US4495175A (en) | Preparation of highly purified human antihemophilic factor | |
| EP0378208B1 (en) | Production method for protein-containing composition | |
| JP3435668B2 (en) | A method for the industrial-scale production of high purity, therapeutically suitable standardized human von Willebrand factor concentrates. | |
| US4656254A (en) | Method of preparing alpha-1-proteinase inhibitor and antithrombin III | |
| US4470969A (en) | Process for producing a concentrate of coagulation factors VII and VIIa | |
| Wickerhauser et al. | Development of Large Scale Fractionation Methods: VII. Preparation of Antithrombin III Concentrate 1 | |
| US7816495B2 (en) | Processes for the preparation of fibrinogen | |
| EP0617049B1 (en) | Process for the isolation of highly purified factors IX, X and II from prothrombin complex or human plasma | |
| JPH0764750B2 (en) | Process for producing alpha-1-proteinase inhibitor | |
| EP0176926A2 (en) | Process for producing a high purity antihemophilic factor concentrate | |
| WO2007046631A1 (en) | Method for manufacturing high purified factor ix | |
| EP0252392A2 (en) | Viral inactivation and purification of active proteins | |
| US6063909A (en) | Preparation of factor IX | |
| ES2224109T3 (en) | PROCEDURE FOR PREPARATION OF HUMAN PROTEIN C ACTIVATED. | |
| Wickerhauser et al. | A Single‐Step Method for the Isolation of Antithrombin III 1, 2 | |
| EP0650364B1 (en) | Purification of factor ix | |
| AU665452C (en) | Purification of factor IX | |
| CN114395032A (en) | Method for extracting human antithrombin III from blood plasma | |
| Wickerhauser et al. | Development of large scale fractionation methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200680039024.1 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3915/DELNP/2008 Country of ref document: IN |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06799311 Country of ref document: EP Kind code of ref document: A1 |